MA27438A1 - Piperazines heterocycliques substituees pour le traitement de la schizophrenie - Google Patents
Piperazines heterocycliques substituees pour le traitement de la schizophrenieInfo
- Publication number
- MA27438A1 MA27438A1 MA28152A MA28152A MA27438A1 MA 27438 A1 MA27438 A1 MA 27438A1 MA 28152 A MA28152 A MA 28152A MA 28152 A MA28152 A MA 28152A MA 27438 A1 MA27438 A1 MA 27438A1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- schizophrenia
- substituted heterocyclic
- piperazines
- heterocyclic piperazines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Abstract
REVENDICATION DE PRIORITES US 17 Septembre 2002 60/411,475 US 4 Octobre 2002 60/416,355 Voir en annexe le titre de l'invention et le texte de l'abrégé Pipérazines hétérocycliques substituées pour le traitement de la schizophrénie La présente invention concerne des composés de formule 1 dans laquelle X, Y, Z, A, R1, R2, R3, R4, R9, W1 et W2 sont tels que définis dans le présent mémoire, des compositions pharmaceutiques les contenant et leur utilisation dans le traitement de troubles du système nerveux central et d'autres affections.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41147502P | 2002-09-17 | 2002-09-17 | |
US41635502P | 2002-10-04 | 2002-10-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27438A1 true MA27438A1 (fr) | 2005-07-01 |
Family
ID=32033549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28152A MA27438A1 (fr) | 2002-09-17 | 2005-03-17 | Piperazines heterocycliques substituees pour le traitement de la schizophrenie |
Country Status (25)
Country | Link |
---|---|
US (1) | US20040138230A1 (fr) |
EP (1) | EP1546143A1 (fr) |
JP (1) | JP2006503106A (fr) |
KR (1) | KR20050057404A (fr) |
AP (1) | AP2005003250A0 (fr) |
AR (1) | AR041260A1 (fr) |
AU (1) | AU2003263413A1 (fr) |
BR (1) | BR0314393A (fr) |
CA (1) | CA2499326A1 (fr) |
CO (1) | CO5550472A2 (fr) |
EA (1) | EA200500342A1 (fr) |
EC (1) | ECSP055676A (fr) |
HR (1) | HRP20050248A2 (fr) |
IS (1) | IS7710A (fr) |
MA (1) | MA27438A1 (fr) |
MX (1) | MXPA05002007A (fr) |
NO (1) | NO20051826L (fr) |
OA (1) | OA12923A (fr) |
PA (1) | PA8582601A1 (fr) |
PE (1) | PE20050132A1 (fr) |
PL (1) | PL375981A1 (fr) |
RS (1) | RS20050195A (fr) |
TW (1) | TW200409771A (fr) |
UY (1) | UY27976A1 (fr) |
WO (1) | WO2004026864A1 (fr) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006508101A (ja) * | 2002-11-08 | 2006-03-09 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | フェニルアルキルおよびピリジルアルキルピペラジン誘導体 |
EP1697334A1 (fr) * | 2003-12-08 | 2006-09-06 | Warner-Lambert Company LLC | Derives d'indane heterocyclique substitue et composes apparentes pour le traitement de la schizophrenie |
EP1701954A1 (fr) * | 2003-12-31 | 2006-09-20 | Warner-Lambert Company LLC | Derives de piperidine et de piperazine n-substitues |
US20050256118A1 (en) * | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
WO2006090273A2 (fr) * | 2005-02-22 | 2006-08-31 | Warner-Lambert Company Llc | [1,8]naphthyridin-2-ones et composes relatifs a liants ceto ou hydroxyl destines au traitement de la schizophrenie |
TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
JP4315393B2 (ja) * | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
TWI329641B (en) | 2005-08-31 | 2010-09-01 | Otsuka Pharma Co Ltd | (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same |
WO2008015516A1 (fr) * | 2006-07-28 | 2008-02-07 | Pfizer Products Inc. | Hétérocycles tricycliques à cycles fusionnés dans le traitement de la schizophrénie |
AR063302A1 (es) * | 2006-10-13 | 2009-01-21 | Otsuka Pharma Co Ltd | Derivados de 4-benzo[b]tiofen-4-il-piperazin-1-il con accion antagonista del receptor 5-ht2a de serotonina y receptor de adrenalina alfa1 y agonista parcial del receptor d2, una composicion farmaceutica que lo comprende y un proceso para producirla. |
JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
JP4785881B2 (ja) * | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
NZ582124A (en) * | 2007-05-21 | 2012-07-27 | Reviva Pharmaceuticals Inc | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents |
US20090281322A1 (en) * | 2008-05-08 | 2009-11-12 | Allergan, Inc. | THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS |
RU2010149311A (ru) | 2008-05-08 | 2012-06-20 | Аллерган, Инк. (Us) | ТЕРАПЕВТИЧЕСКИ ПОЛЕЗНЫЕ ЗАМЕЩЕННЫЕ 1,7-ДИФЕНИЛ-1,2,3,5,6,7-ГЕКСАГИДРОПИРИДО [3,2,1-ij]ХИНОЛИНОВЫЕ СОЕДИНЕНИЯ |
EP2322520A4 (fr) * | 2008-07-28 | 2012-04-25 | Jiangsu Guohua Invest Co Ltd | Dérivés de pipéridine ou de pipérazine substitués par aralkyle et leurs utilisations pour le traitement de la schizophrénie |
MX2011002628A (es) * | 2008-09-22 | 2011-04-05 | Hoffmann La Roche | Moduladores de los receptores d3 y 5-ht2a de piperazina. |
CN102164914A (zh) * | 2008-09-23 | 2011-08-24 | 弗·哈夫曼-拉罗切有限公司 | 用作多巴胺D3受体调节剂的苯并[d]异*唑-3-基-哌嗪衍生物 |
AU2014265021B2 (en) * | 2009-06-25 | 2016-07-21 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds |
FI2445502T4 (fi) | 2009-06-25 | 2023-01-13 | Heterosyklisiä yhdisteitä neurologisten ja psykologisten häiriöiden hoitamiseksi | |
JP5732453B2 (ja) | 2009-06-25 | 2015-06-10 | アルカーメス ファーマ アイルランド リミテッド | Nh酸性化合物のプロドラッグ |
TWI503323B (zh) | 2010-03-29 | 2015-10-11 | Oncotherapy Science Inc | 三環化合物以及含此化合物之pbk抑制劑 |
US8877778B2 (en) | 2010-12-15 | 2014-11-04 | Hoffmann-La Roche Inc. | Benzofurane compounds |
PL3156056T3 (pl) | 2011-03-18 | 2024-04-29 | Alkermes Pharma Ireland Limited | Kompozycje farmaceutyczne zawierające estry sorbitanu |
US8921397B2 (en) | 2011-05-04 | 2014-12-30 | Hoffmann-La Roche Inc. | Benzofurane-piperidine compounds |
BR112014001520B1 (pt) | 2011-07-28 | 2022-05-10 | Otsuka Pharmaceutical Co., Ltd | Processo para a produção de composto de benzo[b]tiofeno |
JO3227B1 (ar) * | 2011-09-08 | 2018-03-08 | Otsuka Pharma Co Ltd | مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان |
US8969337B2 (en) | 2011-12-15 | 2015-03-03 | Alkermes Pharma Ireland Limited | Prodrugs of secondary amine compounds |
NZ630643A (en) | 2012-03-19 | 2017-08-25 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising fatty acid esters |
AU2013235523B9 (en) | 2012-03-19 | 2018-01-04 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising glycerol esters |
AU2013235526B2 (en) | 2012-03-19 | 2017-11-30 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
NZ631345A (en) | 2012-09-19 | 2017-06-30 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions having improved storage stability |
WO2015143145A1 (fr) | 2014-03-20 | 2015-09-24 | Alkermes Pharma Ireland Limited | Formulations d'aripiprazole présentant des vitesses d'injection plus élevées |
JP5714152B2 (ja) * | 2014-03-26 | 2015-05-07 | 江蘇恒誼薬業有限公司 | アラルキルピペリジン(又はピペラジン)誘導体及びその統合失調症治療のための使用 |
CN106608875A (zh) * | 2015-10-26 | 2017-05-03 | 江苏恩华药业股份有限公司 | 一种稠和杂环类衍生物合成及其应用 |
CN106749219A (zh) | 2015-11-20 | 2017-05-31 | 江苏恩华药业股份有限公司 | 一种内酰胺类衍生物及其应用 |
AU2019230014A1 (en) | 2018-03-05 | 2020-09-17 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
CN113727968A (zh) * | 2019-05-14 | 2021-11-30 | 杏林制药株式会社 | 4-氧代吡咯烷-3-甲酰胺衍生物的制备方法 |
WO2021098737A1 (fr) * | 2019-11-18 | 2021-05-27 | 上海枢境生物科技有限公司 | Dérivé hétérocyclique fusionné et son utilisation |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3706427A1 (de) * | 1987-02-27 | 1988-09-08 | Boehringer Mannheim Gmbh | Neue substituierte 3h-indole, zwischenprodukte, verfahren zu ihrer herstellung sowie arzneimittel |
GB8723763D0 (en) * | 1987-10-09 | 1987-11-11 | Hydro Tech Ltd | Liquid flow control device |
US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
US5364866A (en) * | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
ATE126512T1 (de) * | 1989-05-19 | 1995-09-15 | Hoechst Roussel Pharma | N-(aryloxyalkyl)heteroarylpiperidine und - heteroarylpiperazine, verfahren zu ihrer herstellung und ihre verwendung als medikamente. |
JP2768981B2 (ja) * | 1989-06-22 | 1998-06-25 | シャープ株式会社 | 光メモリ素子 |
WO1991000863A1 (fr) * | 1989-07-07 | 1991-01-24 | Pfizer Inc. | Agents antipsychotiques a base de piperazine d'heteroaryle |
US5350747A (en) * | 1989-07-07 | 1994-09-27 | Pfizer Inc | Heteroaryl piperazine antipsychotic agents |
US5147881A (en) * | 1990-11-14 | 1992-09-15 | Pfizer Inc | 4-(1,2-benzisoxazolyl)piperidine antipsychotic agents |
US5143923B1 (en) * | 1991-04-29 | 1993-11-02 | Hoechst-Roussel Pharmaceuticals Incorporated | Benzoisothiazole-and benzisoxazole-3-carboxamides |
AU645681B2 (en) * | 1991-05-02 | 1994-01-20 | John Wyeth & Brother Limited | Piperazine derivatives |
IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
TW300219B (fr) * | 1991-09-14 | 1997-03-11 | Hoechst Ag | |
US5206366A (en) * | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
UA57734C2 (uk) * | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
IL125951A (en) * | 1997-09-05 | 2003-09-17 | Pfizer Prod Inc | A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal |
DE19746612A1 (de) * | 1997-10-22 | 1999-04-29 | Basf Ag | 2-Substituierte 1,2-Benzisothiazol-Derivate, ihre Herstellung und Verwendung |
IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
US6387904B2 (en) * | 1998-05-18 | 2002-05-14 | Pfizer Inc | Method of treating glaucoma and ischemic retinopathy |
EP1194425B1 (fr) * | 1999-06-23 | 2005-08-10 | Aventis Pharma Deutschland GmbH | Benzimidazoles substitues |
-
2003
- 2003-09-05 EA EA200500342A patent/EA200500342A1/ru unknown
- 2003-09-05 OA OA1200500072A patent/OA12923A/en unknown
- 2003-09-05 AP AP2005003250A patent/AP2005003250A0/xx unknown
- 2003-09-05 PL PL03375981A patent/PL375981A1/xx not_active Application Discontinuation
- 2003-09-05 CA CA002499326A patent/CA2499326A1/fr not_active Abandoned
- 2003-09-05 JP JP2004568902A patent/JP2006503106A/ja active Pending
- 2003-09-05 AU AU2003263413A patent/AU2003263413A1/en not_active Abandoned
- 2003-09-05 EP EP03797433A patent/EP1546143A1/fr not_active Withdrawn
- 2003-09-05 MX MXPA05002007A patent/MXPA05002007A/es unknown
- 2003-09-05 RS YUP-2005/0195A patent/RS20050195A/sr unknown
- 2003-09-05 KR KR1020057004592A patent/KR20050057404A/ko active IP Right Grant
- 2003-09-05 BR BR0314393-7A patent/BR0314393A/pt not_active IP Right Cessation
- 2003-09-05 WO PCT/IB2003/003902 patent/WO2004026864A1/fr not_active Application Discontinuation
- 2003-09-12 PE PE2003000930A patent/PE20050132A1/es not_active Application Discontinuation
- 2003-09-12 US US10/660,908 patent/US20040138230A1/en not_active Abandoned
- 2003-09-15 AR ARP030103336A patent/AR041260A1/es unknown
- 2003-09-15 UY UY27976A patent/UY27976A1/es not_active Application Discontinuation
- 2003-09-15 PA PA20038582601A patent/PA8582601A1/es unknown
- 2003-09-16 TW TW092125508A patent/TW200409771A/zh unknown
-
2005
- 2005-02-24 IS IS7710A patent/IS7710A/is unknown
- 2005-03-15 EC EC2005005676A patent/ECSP055676A/es unknown
- 2005-03-16 HR HR20050248A patent/HRP20050248A2/hr not_active Application Discontinuation
- 2005-03-17 MA MA28152A patent/MA27438A1/fr unknown
- 2005-03-18 CO CO05025665A patent/CO5550472A2/es not_active Application Discontinuation
- 2005-04-15 NO NO20051826A patent/NO20051826L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IS7710A (is) | 2005-02-24 |
PE20050132A1 (es) | 2005-03-21 |
MXPA05002007A (es) | 2005-04-28 |
AU2003263413A1 (en) | 2004-04-08 |
EA200500342A1 (ru) | 2005-08-25 |
EP1546143A1 (fr) | 2005-06-29 |
PA8582601A1 (es) | 2004-05-26 |
UY27976A1 (es) | 2004-04-30 |
AR041260A1 (es) | 2005-05-11 |
CA2499326A1 (fr) | 2004-04-01 |
TW200409771A (en) | 2004-06-16 |
NO20051826L (no) | 2005-04-15 |
HRP20050248A2 (en) | 2005-10-31 |
KR20050057404A (ko) | 2005-06-16 |
OA12923A (en) | 2006-10-13 |
US20040138230A1 (en) | 2004-07-15 |
AP2005003250A0 (en) | 2005-03-31 |
ECSP055676A (es) | 2005-07-06 |
RS20050195A (en) | 2007-08-03 |
WO2004026864A1 (fr) | 2004-04-01 |
PL375981A1 (en) | 2005-12-12 |
BR0314393A (pt) | 2005-07-19 |
CO5550472A2 (es) | 2005-08-31 |
JP2006503106A (ja) | 2006-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27438A1 (fr) | Piperazines heterocycliques substituees pour le traitement de la schizophrenie | |
MA26875A1 (fr) | Composes azapolycycliques a noyau aryle condensé | |
MA31373B1 (fr) | Composes amino-heterocycliques | |
MA27439A1 (fr) | Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase | |
MEP45308A (en) | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | |
MA27596A1 (fr) | Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation | |
MA33053B1 (fr) | Inhibiteurs de la poly(adp-ribose) polymerase (parp) | |
ES2216266T3 (es) | 1-fenil-4-bencilpiperazinas: ligandos especificos del subtipo receptorde dopamina d4. | |
MA28094A1 (fr) | Dérivés [3.1.0] bicycliques servant d'inhibiteurs du transporteur de glycine | |
MA27568A1 (fr) | Derives de pyrrolopyrimidine | |
MA27774A1 (fr) | Inhibiteurs de phosphatidylinositol 3-kinase | |
MA27675A1 (fr) | Derives de piperazine et leur utilisation dans le traitement de maladies neurologiques et psychiatriques | |
TN2010000175A1 (fr) | Piperidino-dihydrothienopyrimidines substituees | |
TNSN04156A1 (fr) | Pyridinones substituees servant de modulateurs de la map-kinase p38 | |
TN2009000204A1 (fr) | Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase | |
TNSN07380A1 (fr) | [3.1.0]heteroarylamides bicycliques servant d'inhibiteurs du transport de glycine de type 1 | |
MA30089B1 (fr) | (arylsulfonyl)-pyrasolopiperidines | |
TNSN05250A1 (fr) | Pyrimidinones substituees | |
TNSN07021A1 (fr) | Derives de quinazoline -4-yl-piperidine et cinnoline -4-yl-piperidine servant d'inhibiteurs de pde10 pour le traitement de troubles du snc | |
MA27582A1 (fr) | Derives benzazepine pour le traitement de troubles neurologiques | |
MA27887A1 (fr) | Dicetopiperazines substituees et leur utilisation comme antagonistes de l'ocytocine | |
MA26957A1 (fr) | Spiro-pyrimidine-2,4,6-triones inhibitrices de metalloproteinases. | |
MA27451A1 (fr) | Derives de thiazole pour le traitement de troubles neurodegeneratifs | |
MA27801A1 (fr) | Nouveaux composes heterocycliques pour le traitement des affections inflammatoires et allergiques, leur procede de preparation et compositions pharmaceutiques les contenant | |
MA32627B1 (fr) | Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase |